Search company, investor...

ESBATech

esbatech.com

Founded Year

1998

Stage

Acquired | Acquired

Total Raised

$22M

Valuation

$0000 

About ESBATech

ESBATech develops therapeutic single-chain fragment antibodies on the basis of its fully human antibody fragments for the treatment of various inflammatory diseases. The established know-how and expertise in antibody engineering is employed for the improvement and optimization of existing fragments for better stability and expression properties.

Headquarters Location

Wagistr. 21

8952,

Switzerland

Missing: ESBATech's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ESBATech's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ESBATech Patents

ESBATech has filed 1 patent.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/21/2017

9/22/2020

Immunology, Immune system, Clusters of differentiation, Monoclonal antibodies, Proteins

Grant

Application Date

9/21/2017

Grant Date

9/22/2020

Title

Related Topics

Immunology, Immune system, Clusters of differentiation, Monoclonal antibodies, Proteins

Status

Grant

Latest ESBATech News

ESBATech's antibody fragments demonstrate penetration into the eye with topical delivery via eye...

Feb 13, 2019

%PDF-1.4 %âãÏÓ11 0 obj > endobjxref11 270000000016 00000 n0000001069 00000 n0000000836 00000 n0000001146 00000 n0000001436 00000 n0000002490 00000 n0000003548 00000 n0000003781 00000 n0000004019 00000 n0000004668 00000 n0000005732 00000 n0000006377 00000 n0000007438 00000 n0000007678 00000 n0000008265 00000 n0000008406 00000 n0000009045 00000 n0000009640 00000 n0000010234 00000 n0000010817 00000 n0000023506 00000 n0000023956 00000 n0000024180 00000 n0000024424 00000 n0000033528 00000 n0000033792 00000 n0000033966 00000 ntrailer ]>>startxref0%%EOF13 0 obj

ESBATech Frequently Asked Questions (FAQ)

  • When was ESBATech founded?

    ESBATech was founded in 1998.

  • What is ESBATech's latest funding round?

    ESBATech's latest funding round is Acquired.

  • How much did ESBATech raise?

    ESBATech raised a total of $22M.

  • Who are the investors of ESBATech?

    Investors of ESBATech include Alcon, HBM Healthcare Investments, Clarus, Novartis Venture Funds, SV Health Investors and 11 more.

  • Who are ESBATech's competitors?

    Competitors of ESBATech include F-star Therapeutics, Gliknik, Sorrento Therapeutics, NeoClone, Adimab and 11 more.

Compare ESBATech to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

A
Adimab

Adimab is engaged in the discovery, maturation and production of therapeutic human antibodies. Per the company, Adimab integrates all aspects of antibody discovery and sophisticated screening methods, and therefore can rapidly discover high affinity antibodies that also behave well in a formulation and manufacturing context. The company states that their proprietary library design and presentation technology allows Adimab to discover full-length human antibodies with broad epitope coverage, high affinity and therapeutic relevance faster than any current technology.

B
Bioventix

Bioventix is a biotechnology company specializing in the development of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics focusing on the areas of clinical diagnostics and drugs of abuse testing.

T
Thermalin

Thermalin engineers new forms of insulin that will lower the burden of insulin use, increase patient adoption of and adherence to insulin therapy, improve patient lives and outcomes, and lower the cost of caring for people with Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D).

NeoClone Logo
NeoClone

NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.

G
Gliknik

Gliknik is a privately held biopharmaceutical company creating new therapies for patients with cancer and immune disorders. Gliknik specializes in the modulation of the immune system to fight disease. The Gliknik clinical compound is the immune modulator GL-0817 for cancer, which is in a randomized, blinded, placebo-controlled study in the prevention of recurrence of high-risk oral cavity cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.